Loading…
Phathom Pharmaceuticals, Inc. is projected to rise to $14.51 by 2027, a +22% move from its current price of $11.92. PHAT is currently trading above its 50-day average (a bullish sign). Technical indicators currently lean strong buy.
A data-driven summary — not financial advice. See the full breakdown below.
Live market data via Yahoo Finance · updated 7/11/2026
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Jul 12 | $11.60 | $11.92 | $12.25 | 0.00% |
| Jul 13 | $11.47 | $11.92 | $12.38 | 0.00% |
| Jul 14 | $11.38 | $11.92 | $12.49 | 0.00% |
| Jul 15 | $11.29 | $11.92 | $12.58 | +0.01% |
| Jul 16 | $11.22 | $11.92 | $12.66 | +0.01% |
| Jul 17 | $11.16 | $11.92 | $12.73 | +0.01% |
| Jul 18 | $11.10 | $11.92 | $12.80 | +0.01% |
| Period | Min | Prediction | Max | Change |
|---|---|---|---|---|
| Week 1 | $11.10 | $11.92 | $12.80 | +0.01% |
| Week 2 | $10.78 | $11.92 | $13.19 | +0.02% |
| Week 3 | $10.54 | $11.92 | $13.49 | +0.03% |
| Week 4 | $10.34 | $11.92 | $13.75 | +0.04% |
| Week 5 | $10.17 | $11.93 | $13.99 | +0.04% |
| Week 6 | $10.01 | $11.93 | $14.20 | +0.05% |
| Week 7 | $9.88 | $11.93 | $14.41 | +0.06% |
Short-term targets derived from the forecast trend and recent volatility. Highly uncertain — not financial advice.
Phathom Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing treatments for gastrointestinal diseases in the United States.
It develops VOQUEZNA, which has completed Phase III clinical trials for the treatment of erosive gastroesophageal reflux disease (GERD) and related heartburn in adults; and VOQUEZNA Triple Pak and VOQUEZNA Dual Pak that have completed Phase III clinical trials for treating Helicobacter pylori, as well as VOQUEZNA and vonoprazan for the treatment of heartburn associated with non-erosive GERD and eosinophilic esophagitis in adults and adolescents.
The company was incorporated in 2018 and is headquartered in Florham Park, New Jersey.
Phathom Pharmaceuticals, Inc. trades in the Healthcare sector with a current price of $12.06 and a market capitalization of $961.86M.
Its rank is 2592 among listed assets.
A major floor 31.9% below — a decisive break under it would weaken the trend.
The nearest floor, 22.5% below — buyers have tended to step in here.
The nearest ceiling, 5.8% above — a clean break opens room to run.
A major ceiling 24.6% above — clearing it would confirm fresh momentum.
Key PHAT support and resistance from recent price action — levels where the trend has historically paused or reversed. Percentages are the distance from the current price.
A snapshot of PHAT market posture derived from its technical indicators and recent volatility. Higher trend and alignment lean bullish; higher risk means larger swings.
Technical Analysis
Indicators computed on daily closing prices.
| Period | SMA | Action | EMA | Action |
|---|---|---|---|---|
| MA 5 | $11.95 | Sell | $12.01 | Sell |
| MA 10 | $11.39 | Buy | $11.59 | Buy |
| MA 20 | $11.00 | Buy | $11.22 | Buy |
| MA 50 | $11.16 | Buy | $11.19 | Buy |
| MA 100 | $11.36 | Buy | $11.55 | Buy |
| MA 200 | $12.72 | Sell | $11.65 | Buy |
| Name | Value | Action |
|---|---|---|
| RSI (14) | 69.14 | Neutral |
| Stoch RSI (14) | 100.00 | Sell |
| CCI (20) | 217.01 | Buy |
| Williams %R (14) | 0.00 | Info |
| MACD (12,26,9) | 0.23 | Buy |
| ROC (12) | 16.11 | Buy |
| Bollinger %B (20,2) | 1.14 | Sell |
| Stochastic %K (14) | 100.00 | Sell |
| TRIX (15) | 0.11 | Buy |
| Awesome (5,34) | 1.26 | Buy |
| Ultimate (7,14,28) | 80.31 | Sell |
| Momentum (10) | 2.27 | Buy |
| Aroon Osc (25) | 80.00 | Buy |
| Hull MA (9) | 12.49 | Sell |
| ADX (14) | 15.47 | Neutral |
| ATR (14) | 0.30 | Info |
The 30-day technical picture shows bullish sentiment, with RSI(14) at 60. The stock’s short-term moving averages sit at $11.12 on the SMA50 and $12.71 on the SMA200, providing nearby reference points for momentum.
Support sits at $9.24 and resistance at $12.06, framing a near-term trading range. Over the last 30 days, the price range has extended from $10.06 to $14.46.
| Year | Min | Avg | Max | ROI | Sentiment |
|---|---|---|---|---|---|
| $9.24 | $11.92 | $15.22 | 0% | Neutral | |
| $11.57 | $14.51 | $19.26 | +22% | Bullish | |
| $13.18 | $17.00 | $23.40 | +43% | Bullish | |
| $15.65 | $20.65 | $29.24 | +73% | Bullish | |
| $17.13 | $23.05 | $33.45 | +93% | Bullish | |
| $17.16 | $23.53 | $34.86 | +97% | Bullish | |
| $18.68 | $26.05 | $39.33 | +119% | Bullish | |
| $18.82 | $26.68 | $40.97 | +124% | Bullish | |
| $21.08 | $30.34 | $47.33 | +155% | Bullish | |
| $27.24 | $39.77 | $62.96 | +234% | Bullish | |
| $32.13 | $50.10 | $84.31 | +320% | Bullish | |
| $61.34 | $107.14 | $197.14 | +799% | Bullish |
Current year — the forecast is anchored to the live price, so ROI shows 0%.
| Month | Min | Avg | Max | Change |
|---|---|---|---|---|
| July 2026 | $9.24 | $11.92 | $14.03 | +0.00% |
| August 2026 | $10.11 | $11.93 | $14.46 | +0.12% |
| September 2026 | $10.04 | $11.93 | $14.62 | -0.01% |
| October 2026 | $9.67 | $11.55 | $14.28 | -3.19% |
| November 2026 | $9.68 | $11.63 | $14.49 | +0.67% |
| December 2026 | $10.05 | $12.13 | $15.22 | +4.31% |
Click any year to see its month-by-month PHAT forecast. Min / Avg / Max are a bear / base / bull scenario; ROI is the projected move from the current price. Change is the month-over-month move in the average. Estimates, not guarantees.
By 2026, PHAT could reach as high as $15.22, with a base case around $11.92 and support toward $9.24 — roughly 0% from $11.92. Price action looks broadly range-bound.
Expect PHAT to range from $11.57 to $19.26 through 2027. The $14.51 average target implies a +22% move from current prices. That is up +22% on the projected 2026 average. Buyers look set to stay in control over this stretch.
The PHAT price prediction for 2028 points to an average of $17.00 (low $13.18, high $23.40) — a potential gain of +43% on today's $11.92. Momentum favours further upside here.
In 2029, PHAT is projected to trade between $15.65 and $29.24, averaging $20.65 — a potential gain of +73% from today's $11.92. That is up +21% on the projected 2028 average. Buyers look set to stay in control over this stretch.
Phathom Pharmaceuticals, Inc.'s 2030 outlook centres on $23.05, within a $17.13 to $33.45 range. That is up +12% on the projected 2029 average. That marks a +93% change versus current levels. Momentum favours further upside here.
By 2031, PHAT could reach as high as $34.86, with a base case around $23.53 and support toward $17.16 — roughly +97% from $11.92. Buyers look set to stay in control over this stretch.
Expect PHAT to range from $18.68 to $39.33 through 2032. The $26.05 average target implies a +119% move from current prices. That is up +11% on the projected 2031 average. Momentum favours further upside here.
The PHAT price prediction for 2033 points to an average of $26.68 (low $18.82, high $40.97) — a potential gain of +124% on today's $11.92. Buyers look set to stay in control over this stretch.
In 2034, PHAT is projected to trade between $21.08 and $47.33, averaging $30.34 — a potential gain of +155% from today's $11.92. That is up +14% on the projected 2033 average. Momentum favours further upside here.
Phathom Pharmaceuticals, Inc.'s 2035 outlook centres on $39.77, within a $27.24 to $62.96 range. That is up +31% on the projected 2034 average. That marks a +234% change versus current levels. Buyers look set to stay in control over this stretch.
By 2040, PHAT could reach as high as $84.31, with a base case around $50.10 and support toward $32.13 — roughly +320% from $11.92. Momentum favours further upside here.
Expect PHAT to range from $61.34 to $197.14 through 2050. The $107.14 average target implies a +799% move from current prices. That is up +114% on the projected 2040 average. Buyers look set to stay in control over this stretch.
Investing $1,000 in PHAT today (≈ 83.892617 PHAT) could be worth
$8,988.54
+$7,988.54 (+799%) by 2050 · US Dollar
Based on the average projected PHAT price of $107.14 in 2050.
Based on the base (average) forecast scenario. FX rates are indicative. Estimates only — not financial advice.
See what a past investment in PHATwould be worth at today's price.
$1,000 invested in PHAT on Jul 10, 2025 (≈ 103.199179 PHAT) would be worth
$1,230.13
+$230.13 (+23.0%) today · 1.23× · US Dollar
Based on a PHAT entry price of $9.69 vs. today's $11.92.
| Invested | Entry price | Value today | Return |
|---|---|---|---|
| 1 week ago | $11.2 | $1,064.29 | +6.4% |
| 1 month ago | $9.82 | $1,213.85 | +21.4% |
| 3 months ago | $12.63 | $943.78 | -5.6% |
| 6 months ago | $14.47 | $823.77 | -17.6% |
| 1 year ago | $9.69 | $1,230.13 | +23.0% |
| All time (5.0y) ago | $34.95 | $341.06 | -65.9% |
Past performance from historical market data — it does not predict future results. FX rates are indicative. Not financial advice.
Enter a price to see how it sits against our PHAT forecast.
Our base-case forecast reaches $24.00 around 2032.
Implied market cap at $24.00: $1.91B
The multi-year forecast paints a rising trajectory with increasingly favorable outlooks across the horizon. In 2030, the average price is projected at $20.57 with a min of $15.22 and a max of $29.97, delivering a 70.6% ROI and a bullish sentiment.
The forecast continues to lift into 2040, where the average is $38.39 and the ROI is 218.4% with a bullish stance, and again in 2050, where the average is $79.94 and the ROI is 562.8% with a bullish outlook. These figures imply substantial upside potential over time, albeit as estimates rather than guarantees.
Tap a question to reveal the answer.
The 2030 forecast shows a min of $15.22, an avg of $20.57, and a max of $29.97, with an ROI of 70.6% and a bullish sentiment.
The forecast indicates a shift to bullish sentiment from 2028 onward and rising averages through 2030, 2040, and 2050 (e.g., avg $20.57 in 2030, $38.39 in 2040, $79.94 in 2050) with increasing ROI, though these are estimates and not guarantees.
Yes. The forecast maximum by 2050 is $148.22, which exceeds $100.
Current price is $12.06 and market cap is $961.86M.
The 30-day range is $10.06 to $14.46.
Phathom Pharmaceuticals, Inc. Community Discussion
0Share your Phathom Pharmaceuticals, Inc. price prediction and read what the community thinks. Be respectful — comments are public and not financial advice.
Be the first to share your prediction…
What's your take? Add a comment above to start the conversation.